S/L: VTVT Up 109% in 2 Days
February 10, 2019
The Insider Report
Trade Alert
As expected, vTv Therapeutics (VTVT)b announced positive results from Phase 2 of its Simplici-T1 study of the drug TTP399.
This has the potential to be the first-in-class adjunctive therapy for patients with Type 1 diabetes.
And the stock responded in kind...
Shares made a peak gain of 109% in just two days.
The stock has retraced a bit in the first hour of trading, but readers still have an open gain of 57% on the position in just four weeks.
I suggest selling half the stock here to lock in profits and raising the stop to protect the rest.
Action to Take: Sell ½ the shares of vTv Therapeutics (VTVT) at the market.
Raise the stop on the rest to $2.50.
Did you make money on this trade? What about the 162% gain on CDLX stock? Or the 1,090% profit on the options?
Send an email to me directly at rossgivens@gmail.com.
Let me know about your biggest Insider Report win and I’ll respond personally.
If you have questions, feel free to shoot an email to support@hubertsenters.com.
All the Best,
Ross Givens
Editor, The Insider Report